Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.

Jared Cohen, Douglas R. Adkins, Jessica Ley et al.|Journal of Clinical Oncology|2023

Cited by 4